Excellent Bleeding Profile in AF Using Factor XI Inhibitor.

Published Date: 14 Nov 2023

Additional information from the phase 2b AZALEA trial of the factor XI inhibitor abelacimab demonstrates that in patients with AF, there are notable decreases in major and clinically meaningful nonmajor bleeding when rivaroxaban is used instead.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Is It Really Cancer? More Concerns About Accelerated Approval; Metformin and Cancer

2.

Pediatric high-grade gliomas: Research reveals effective targeting with avapritinib

3.

In prostate cancer survivorship, sleep disturbances are underappreciated.

4.

Study shows supervised exercise improves strength, physical performance in patients with advanced breast cancer

5.

a cutting-edge cancer diagnostic tool.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot